ZNTL

1.3600.00%
SD

Scott D. Myers

Independent Chairman of the Board

Mr. Scott D. Myers, M.B.A, is Chairman of Umoja BioPharma, Inc. from November 2024. He serves as the Chairman of the Board at Zentalis Pharmaceuticals, Inc. since November 2024. He has been the Chairman of the Board at Convergent Therapeutics Inc. since March 2024. He served as President & Chief Executive Officer at Viridian Therapeutics, Inc. from February 6, 2023 to October 29, 2023 and served as its Director from February 6, 2023 to October 29, 2023. Mr. Myers served as Chair of board of Ironshore Therapeutics Inc. (formerly known as Highland Therapeutics Inc.) since April, 2022 and Ironshore Pharmaceuticals & Development, Inc. He had been Independent Chairman of Sensorion SA since December 19, 2021 until April 2023. He was Director of Cartesian Therapeutics, Inc. until November 21, 2023. He served as a Senior Advisor at Qiming Venture Partners USA till 2023. He served as an Independent Chairman at Dynavax Technologies Corporation since October 2021 until February 10, 2026. He served as an Independent Director of Trillium Therapeutics Inc. since April 28, 2021 until September 2021. He has been an Independent Director of Selecta Biosciences, Inc. since June 14, 2019. Mr. Myers served as President, Chief Executive Officer and Director at AMAG Pharmaceuticals, Inc. since April 28, 2020 until November 16, 2020. He served as an Independent Director of Harpoon Therapeutics, Inc. since August 2018 and also served as Chairman of the Board since October 2021. Mr. Myers served as the Chairman of the Board at Rainer Theraputics, Inc. (formerly, BioClin Therapeutics, Inc.) since June 2018 until January 2020 and had been its Chief Executive Officer since September 18, 2018 until January 2020 and served as its President since June 2018. He has also served as Chairman of the Board and Chief Executive Officer of Rainier Therapeutics, where he led the sale of Vofatamab to Fusion Pharmaceuticals (FUSN). He serves as an Industry Advisor at EQT. He served as Senior Vice President of Strategic Marketing & Commercialization at Dov Pharmaceutical Inc. from December 14, 2005 to January 15, 2007. He held senior management roles in Johnson & Johnson from 2000 to 2005. He served as General Manager of McNeil Specialty Pharmaceuticals. He served as Chief Executive Officer, President and Director at Cascadian Therapeutics, Inc. from April 4, 2016 to March 9, 2018. From January 2007 to August 2011, he served as a Vice President and Head of European Mid-Markets at UCB S.A. Mr. Myers served as Chief Executive Officer at Aerocrine AB from September 14, 2011 to July 2015 and served as its President since September 14, 2011. He served as Senior Vice President at Ortho Biotech Products, L.P. responsible for new business, new product development, strategic services and sales operations. He served as Senior Vice President and Chief Information Officer of Johnson & Johnson Pharmaceutical Research & Development, where he reported directly to the Chairman and oversaw a global staff of 200 and systems operations in the United States, Europe and Asia. Mr. Myers co-founded ISO Health Care Group. He also has held positions at Baxter Healthcare and Andersen Consulting. He served as Director at Orexo AB (publ) from April 11, 2012 to April 2014. Mr. Myers holds a B. A in Biology from Northwestern University in Evanston, Illinois and a Master of Business Administration from The University of Chicago Graduate School of Business (Booth) in Chicago, Illinois.

Positions